Find information on thousands of medical conditions and prescription drugs.

Cefepime

Cefepime is a fourth generation intravenous cephalosporin antibiotic developed in 1994. Cefepime has broad spectrum activity against Gram positive and Gram negative bacteria. It has good activity against Pseudomonas aeruginosa, Staphylococcus aureus, and multiple drug resistant Streptococcus pneumoniae. A particular strength is its activity against Enterobacteriaceae. more...

Home

Caduet

Calan

Campath

Capoten

Cardura

Casodex

Cathine

Ceclor

Cefotan

Cefzil

Celexa

Cerebyx

Chenodeoxycholic acid

Cholac

Choriogonadotropin alfa

Chorionic gonadotropin

Cialis

Cipro

Climara

Clomid

Colyte

Commit

Coreg

Corgard

Cotrim

Cozaar

Crestor

Cylert

Cytotec

Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected. Cefepime is commonly used to treat severe nosocomial pneumonia and neutropenic fever.

Cefepime is marketed under the trade names Maxipime, Maxcef, Cepimax, Cepimex, and Axepim.

Read more at Wikipedia.org

• [List your site here Free!]


		Cefepime induced bone marrow suppression in a child with osteomyelitis.(Section on Pediatric and Adolescent Medicine) : An article from: Southern Medical Journal $5.95


	Cefepime MIC as a predictor of the extended-spectrum [beta]-lactamase type in Klebsiella pneumoniae, Taiwan - Dispatches To guide selection of carbapenems or fourth-generation cephalosporins as therapy, 110 Klebsiella pneumoniae isolates with extended-spectrum [beta]-lactamases ... From Emerging Infectious Diseases, 5/1/02 by Wen Liang Yu

	CareNet Offering Information on Daiichi Pharmaceutical's Sunrhythm and Bristol-Myers' Maxipime Through Its Online Service Tokyo, Japan, Nov 25, 2005 - (JCNN) - Japanese healthcare solution provider CareNet announced on November 24 that it has added two new items to e-Detailing, ... From JCNN News Summaries, 11/25/05

	Clinical and treatment patterns among 398 patients with ventilator-associated pneumonia: final results of the assessment of local antimicrobial resistance PURPOSE: ALARM was a prospective, observational, cohort study designed to capture and analyze management and outcome variable patterns for ventilator-associated ... From CHEST, 10/1/05 by Marin H. Kollef

	Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results Objective: To evaluate antibiotic utilization and clinical outcomes among patients with clinically suspected ventilator-associated pneumonia (VAP) and ... From CHEST, 10/1/05 by Marin H. Kollef

	A shocking pain in the neck INTRODUCTION: Staphylococcal scalded skin syndrome (SSSS) is an exceedingly rare diagnosis in adults, with fewer than fifty cases reported in the literature. From CHEST, 10/1/05 by Allen J. Blaivas

	Clinical characteristics and risk factors of mortality among severe burn patients with isolates of vancomycin-resistant enterococci PURPOSE: Vancomycin-resistant enterococci (VRE) are multi-drug resistant organisms that have emerged as important nosocomial pathogens in recent years. From CHEST, 10/1/05 by Heung J. Woo

	Phenotypic characteristics of clinical isolates of Klebsiella pneumoniae & evaluation of available phenotypic techniques for detection of extended Background & objectives: Identifying organisms that harbour extended spectrum beta lactamases (ESBLs) is a major challenge for a diagnostic clinical microbiology ... From Indian Journal of Medical Research, 10/1/05 by Manchanda, Vikas

	Predictors of death among patients with ventilator-associated pneumonia: an analysis of the assessment of local antimicrobial resistance measures study PURPOSE: To identify predictors of death among patients with clinically diagnosed ventilator-associated pneumonia. METHODS: ALARM was a prospective, ... From CHEST, 10/1/05 by Lee E. Morrow

Home

Contact

Resources

Exchange Links

ebay